Dr. Steven M. Duffy, MD
Internal Medicine (Internal Medicine Physician)
- Medicare participating
At a glance
- Years since graduation
- 20
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 882
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
NY license 251381
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University Hospital S U N Y Health Science Center Syracuse, NY
- St Joseph's Hospital Health Center Syracuse, NY
- Crouse Hospital Syracuse, NY
- Oswego Hospital Oswego, NY
- Auburn Community Hospital Auburn, NY
Medical groups
- Hematology-Oncology Associates of Cny, PC (64 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 882
- Services billed
- 167,004
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, ferric carboxymaltose, 1 mg | 27,750 | 29 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 19,463 | 89 |
| Injection, aprepitant, 1 mg | 7,800 | 49 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 7,740 | 21 |
| Injection, nivolumab, 1 mg | 7,014 | 17 |
| Injection, oxaliplatin, 0.5 mg | 6,209 | 17 |
| Injection, pembrolizumab, 1 mg | 6,202 | 21 |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 5,580 | 14 |
| Injection, denosumab, 1 mg | 3,960 | 31 |
| Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | 3,050 | 27 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in East Syracuse, NY | 23 |
| Xarelto (rivaroxaban) Other prescribers in East Syracuse, NY | 21 |
| Eliquis (apixaban) Other prescribers in East Syracuse, NY | 20 |
| Hydroxyurea Other prescribers in East Syracuse, NY | 18 |
| Gabapentin Other prescribers in East Syracuse, NY | 15 |
| Tamoxifen Citrate Other prescribers in East Syracuse, NY | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 2 payments worth $85.56 in total to this clinician.
| Novocure Inc. | $65.56 |
|---|---|
| Aveo Pharmaceuticals, Inc. | $20.00 |
| Food and Beverage | $65.56 |
|---|---|
| Education | $20.00 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Aveo Pharmaceuticals, Inc. Mar 12, 2025 | Education FOTIVDA · Oncology · in-kind | $20.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $125,035 in research payments for these studies, mostly to the institutions running them.
- Artemide Lung02 a phase III global study of rilvegostomig or pembrolizumab for patients with metastatic squamous non small cell lung cancer
AstraZeneca Pharmaceuticals LP - A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer ARTEMIDE-Lu…
AstraZeneca Pharmaceuticals LP - A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase in…
AstraZeneca Pharmaceuticals LP - A phase 3 randomized openlabel multicenter trial of ARV471 PF07850327 vs fulvestrant in participants with estrogen receptorpositive HER2NEGATIVE advanced breast cancer whose disease progressed after prior endocrine ba…
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.